InvestorsHub Logo
Followers 33
Posts 2859
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Tuesday, 10/01/2019 6:31:53 PM

Tuesday, October 01, 2019 6:31:53 PM

Post# of 932
SITC (P417) ATLAS™ identifies relevant neoantigens for therapeutic anti-tumor vaccination and may serve as a biomarker for efficacy of immunotherapy of solid tumors

(P420) Broad immunogenicity from GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumor neoantigens

(P678) Vaccine neoantigens empirically identified through the ex vivo ATLAS platform promote potent therapeutic responses to cancer in mice